Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Return-on-Tangible-Equity is 4.86% as of Mar. 2026, which is 87% below its 10-year median of 38.71. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 187 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 72.19% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Invicta Diagnostic's annualized net income for the quarter that ended in Mar. 2026 was ₹18.1 Mil. Invicta Diagnostic's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹372.7 Mil. Therefore, Invicta Diagnostic's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.86%.
The historical rank and industry rank for Invicta Diagnostic's Return-on-Tangible-Equity or its related term are showing as below:
NSE:INVICTA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 15.21 Med: 38.71 Max: 40.21
Current: 16.51
During the past 3 years, Invicta Diagnostic's highest Return-on-Tangible-Equity was 40.21%. The lowest was 15.21%. And the median was 38.71%.
NSE:INVICTA's Return-on-Tangible-Equity is ranked better than 72.19% of 187
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.34
vs NSE:INVICTA: 16.51
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Invicta Diagnostic Return-on-Tangible-Equity Related Terms
Invicta Diagnostic Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INVICTA vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.86% mean?
Invicta Diagnostic (NSE:INVICTA) has a Return-on-Tangible-Equity of 4.86% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Invicta Diagnostic and its competitors. This is 87% below median its historical median of 38.71. Over the past decade, Invicta Diagnostic's Return-on-Tangible-Equity has ranged from 15.21 to 40.21. According to the industry distribution chart, Invicta Diagnostic ranks #52 out of 187 companies in the Medical Diagnostics & Research industry, placing it in the top 27.8%.
Is Invicta Diagnostic's Return-on-Tangible-Equity too high?
Invicta Diagnostic's current Return-on-Tangible-Equity of 4.86% is 87% below median its 10-year median of 38.71. Over the past 10 years, this metric has ranged from a low of 15.21 to a high of 40.21. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.34. Invicta Diagnostic's value of 4.86% is 1329.4% above this industry median. Based on the distribution chart, Invicta Diagnostic ranks #52 out of 187 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #52 out of 187 companies for Return-on-Tangible-Equity. This puts Invicta Diagnostic in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.34. Invicta Diagnostic's value of 4.86% is 1329.4% above this benchmark. Historically, Invicta Diagnostic's own Return-on-Tangible-Equity has ranged from 15.21 to 40.21 over the past decade. While the company's 10-year median is 38.71 vs. the industry median of 0.34, Invicta Diagnostic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.34, based on 187 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current Return-on-Tangible-Equity of 4.86% is 1329.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Return-on-Tangible-Equity is 4.86%, which is 87% below median its own 10-year median of 38.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Return-on-Tangible-Equity of 4.86%. The current Return-on-Tangible-Equity is 4.86%, which is 87% below median its 10-year median of 38.71 and 1329.4% above the Medical Diagnostics & Research industry median of 0.34. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Return-on-Tangible-Equity is 4.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
